The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | Real-world results of an in-class transition from VRd to IRd in myeloma
Joshua Richter, MD, Mount Sinai Medical Center, New York, NY, reports the efficacy and safety results of a study (NCT03173092) investigating a transition from parenteral bortezomib-based treatment to oral ixazomib-based treatment (ixazomib-lenalidomide-dexamethasone) (IRd) for multiple myeloma patients. While beneficial to outcomes, long-term parenteral proteasome inhibitor treatment can be burdensome due to intravenous administration, requirement for hospital-based treatment, and toxicity. The study assessed an in-class transition, hoping to increase treatment duration whilst maintaining quality of life. Of the 101 patients enrolled to date, mean therapy duration was over 1-year, and the overall response rate increased from 62% after bortezomib induction, to 71% on IRd. The results demonstrate the utility and tolerability of an in-class transition which improved treatment duration and responses in a community setting. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020
Disclosures
Joshua Richter, MD, has undertaken consultancy work for Takeda.
